ReviewDrugs2019
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 72 citations in OpenAlex.
- Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation.Frontiers in endocrinology · 2023Trial
- Dual‑targeted radioligand therapy with [European journal of nuclear medicine and molecular imaging · 2026Article
- Presacral Neuroendocrine Tumor Treated With a Combined Robotic Dissection and Kraske Procedure: A Case Report.Cureus · 2025Article
- Mechanistic role of miR-375 in regulating PDPK1 to promote progression of small bowel neuroendocrine tumors: a silico analysis.Discover oncology · 2025Article
- The Evolving Landscape of GEP-NENs in the Era of Precision Oncology: Molecular Insights into Tumor Heterogeneity.Cancers · 2025Review
- Charting the Course: Insights into Neuroendocrine Tumor Dynamics in the United States.Annals of surgery · 2025Article
- Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions.Discover oncology · 2025Review
- Menin: from molecular insights to clinical impact.Epigenomics · 2025Review
- Assessing the diagnostic, prognostic, and therapeutic potential of the somatostatin/cortistatin system in glioblastoma.Cellular and molecular life sciences : CMLS · 2025Article
- Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer.Scientific reports · 2025Article
- Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.Oncology and therapy · 2025Article
- A case report: enhanced somatostatin receptor expression in metastatic pancreatic neuroendocrine tumor following everolimus therapy.Frontiers in cell and developmental biology · 2025Article
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- Alteration of the immunophenotype and cytokine profiles in patients affected by neuroendocrine neoplasms.Endocrine · 2024Article
- Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?International journal of molecular sciences · 2024Article
- Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment.Frontiers in endocrinology · 2024Review
- Metformin in the treatment of colorectal cancer and neuroendocrine tumours.Contemporary oncology (Poznan, Poland) · 2024Review
- The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.Cancers · 2023Review
- Predictors of Long-Term Outcomes After Liver Transplantation for Unresectable Metastatic Neuroendocrine Tumors.Annals of transplantation · 2023Article
- A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in the bronchial and gastrointestinal tract and can produce hormones leading to distinct clinical syndromes. Systemic treatment of patients with unresectable NETs aims to control symptoms related to hormonal overproduction and tumor growth. In the last decades prognosis has improved as a result of increased detection of early stage disease and the introduction of somatostatin analogs (SSAs) as well as several new therapeutic options. SSAs are the first-line medical treatment of NETs and can control hormonal production and tumor growth. The development of next-generation multireceptor targeted and radiolabelled somatostatin analogs, as well as target-directed therapies (as second-line treatment options) further improve progression-free survival in NET patients. To date, however, a significant prolongation of overall survival with systemic treatment in NET has not been convincingly demonstrated. Several new medical options and treatment combinations will become available in the upcoming years, and although preliminary results of preclinical and clinical trials are encouraging, large, preferrably randomized clinical studies are required to provide definitive evidence of their effect on survival and symptom control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.